The cell and gene therapy market is evolving with a focus on developing treatments for larger patient populations. However, this growth poses challenges such as the need for specialized infrastructure and high treatment costs. As clinical benefits and cost-effectiveness become crucial factors, comparisons with traditional drugs are inevitable. In oncology, there is a transition from autologous to allogeneic therapies, particularly in blood cancers. The introduction of off-the-shelf allogeneic therapies could increase accessibility to these treatments compared to current options.
Looking ahead, the shift towards allogeneic therapies opens up new possibilities for expanding access to cell and gene therapies. As the market continues to grow, establishing clinical efficacy and cost-effectiveness will be key in navigating the evolving landscape of treatment options. With advancements in technology and changing treatment paradigms, the future of cell and gene therapy holds promise for improved patient outcomes and expanded therapeutic opportunities.
Read more from pharmaceutical-technology.com
